MMED vs PODD
MMED: MiniMed is a dedicated diabetes technology company providing automated insulin delivery and smart injection systems to improve glycemic control for patients worldwide. PODD: Insulet provides the Omnipod system, a revolutionary tubeless, wearable insulin pump platform that simplifies diabetes management through automated insulin delivery.
Side-by-side fundamentals
| Metric | MMED | PODD | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $19.80 | $134.47 | |
| Market cap | $5.6B | $9.3B | |
| P/E as of 2026-10-08 | n/a | 25.16 | |
| Net margin | -10.7% | +9.1% | PODD higher |
| Gross margin | +54.2% | +71.6% | PODD higher |
| Operating margin | -6.1% | +17.5% | PODD higher |
| ROE | -9.2% | +16.3% | PODD higher |
| ROA | -7.2% | +7.7% | PODD higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.63 | MMED lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +29.4% | |
| Revenue CAGR (3y) SEC XBRL | +12.1% | +27.5% | PODD higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.84 | 0.64 | |
| 1-year return as of 2026-10-08 close | n/a | -57.4% |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.